Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1PM2PP5_Moderate
The NM_013335.4(GMPPA):c.118delC(p.His40IlefsTer30) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★). Variant results in nonsense mediated mRNA decay.
GMPPA (HGNC:22923): (GDP-mannose pyrophosphorylase A) This gene is thought to encode a GDP-mannose pyrophosphorylase. This enzyme catalyzes the reaction which converts mannose-1-phosphate and GTP to GDP-mannose which is involved in the production of N-linked oligosaccharides. [provided by RefSeq, Jul 2008]
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 2-219500196-AC-A is Pathogenic according to our data. Variant chr2-219500196-AC-A is described in ClinVar as [Pathogenic]. Clinvar id is 2769661.Status of the report is criteria_provided_single_submitter, 1 stars.
Alacrima, achalasia, and intellectual disability syndrome Pathogenic:1
Oct 17, 2023
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing
This sequence change creates a premature translational stop signal (p.His40Ilefs*30) in the GMPPA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GMPPA are known to be pathogenic (PMID: 24035193). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with GMPPA-related conditions. For these reasons, this variant has been classified as Pathogenic. -